ncp cardiovascular disease

8/18/2019 NCP Cardiovascular Disease

1/14

SCIENTIFIC METHOD : NCP-INTERMONEV CLINIC

CARDIOVASCULAR DISEASE

Kelompok 1

Erika Nr!i"ri 1#$%&%'%%111%1'


2/14

LEMBAR KESEDIAAN AKTIF

Saa a(2 6er"a()a "a(2a( )i6a+a* i(i "ela* 6erko("ri6/i ak"i! )alam me(2er,aka(

/")i ka// i("ermo(e4 kli(ik "e("a(2 MNT pa)a 7Car)io4a/8lar )i/ea/e9

Erika Nr!i"ri;

1#$%&%'%%111%1'

I()a* D+i,aa("i;

1#$%&%'%1111%%.

Dia* P/pa;

1#$%&%'%1111%1%

L* 0e)e Dia* er)*a/""i;

1#$%&%'%1111%1'


3/14

FORM NUTRITIONAL CARE PROSES

Nama : T(< MM =e(i/ kelami( : Laki-laki

Umr : #1 "* Dia2(o/a Me)i/ : Coro(ar Ar"er Di/ea/e po/" /"emi a("erior

e!/i!; Hiper"e(/i

DATA DASAR IDENTIFIKASI

MASALAH

DIA0NOSA INTERVENSI RENCANA MONEV

A("ropome"ri

>> : 33?$k2

T> : 1&% 8m

>iokimia

Da"a la6 Nilai

(ormal

Ha/il

pemerik/aa(

A/< Ura" '?$-&?%

m2@)l

3?5 m2@)l

HDL '$ m2@)l 53 m2@)l

LDL B1'% m2@)l 1&5 m2@)lT0 B1$% m2@)l 5%1 m2@)l

Kole/"er

ol

B5%% m2@)l 5.m2@)l

IMT : '%?. o6e/e

"i(2ka" 5;

A/am ra" :

HDL :

LDL :

T0 :

Kole/"erol :

Teka(a( )ara* :

NI $


4/14

Fi/ik Kli(i/

Pemerik/aa( Ha/il

KU >aik

Ke/a)ara( Compo/me("i/

Teka(a( )ara* 1%@1%% mmH2

Na)i 1%1@me(i"

RR 5@me(i"

S6,ek"i! Neri )a)a /e6ela*

kiri ;

Se/ak (a!a/ ;

RPD Hiper"e(/i

Die"arDa*l

-Maka(a( pokok : (a/i J'@*ari 5%% 2

-Lak *e+a(i : "elr J#-$@mi(22 $% 2? ika(

keri(2 )a( 6a/a* J5-' kali@mi(22 $% 2

- Lak (a6a"i : "empe J'@*ari '%-$% 2? "a*

J'@*ari '%-$% 2

-Sar : /ara( *i,a J5@*ari 5$-$% 2?Sara( ka8a(2-ka8a(2a( J5@mi(22 5% 2?

+or"el J5@mi(22 $% 2? "oma"

J5@mi(22 $% 2- >a* : pi/a(2 J1-5@mi(22 $% 2r? pepaa

J1-5@mi(22 1%% 2r? apel@,erk@pir J1-

5@mi(22 1$% 2r

- Seli(2a( : ro"i J5@mi(22 #%-3% 2?

2ore(2a( J1@*ari 5-' 6a*

"i(22i

Na)i : "a8*8ar)ia

RR : Ta8*p(ea

Neri )a)a/e6ela* kiri ;?

Se/ak (a!a/ ;

Die"ar

P : #3G ;

KH : 11# G ;

Lemak ,e(* : '.

G ;

Pa/ie( /ka

me(2o(/m/i

maka(a( "i(22i

pri(

U)a(2@kera(2@ke

pi"i(2 ;

Pa/ie( 2emar

me(2ko(/m/i

2ore(2a( )a(

maka(a(

ke6"*a( )a( ka)ar T0

5%1 m2@)l

NI $D 1


5/14

Lai(-lai( : Te* ma(i/ 5@*ari? kopi '@*ari

Se,ak $ "a*( a(2 lal pa/ie( memiliki

ke6ia/aa( maka( k(i(2 "elr me("a*? Pa/ie(

"i)ak memiliki aler2i

Sekara(2

Re8all Peme(*a(

E : 13'%?& kkal E : .3?.G

P : ''? 2 P : #3G

L : #.?' 2 L : .$ G

KH: '1? 2 KH: 11# G

Lemak ,e(* : 1.?'' 2 Lemak ,e(* : '.G

Kole/"erol : 1$? 2 Kole/"erol : &3G

O6a"

Mi(i a/pi 13% m2

Clopi)e 1&$ m2

Cap"opril '5$ m2Sim4a/"a"i(

>i/8or

ISDN

Diaepam

6er/a("a( /m6er

lemak ,e(*;

Pa/ie( 2emar

me(2ko(/m/i

k(i(2 "elrme("a* /m6er

kole/"erol;

− Cap"opril

'5$ m2

me(e6a6ka

( per6a*a(

i()era pe(2e8ap?

me(e6a6ka

( pe(r(a(a/pa(

maka(?

pe(r(a(

>> )a(

)a( "eka(a( )ara*

1%@1%% mmH2

N> 1 5


6/14

a("a2o(i/ 4i"

>

− Sim4a/"a"i(

)iim6a(2i

)e(2a(

maka(a( 6er/era"

"i(22i )a(

me(2*i()ari

,/ ,erk

− Diaepam

me(e6a6ka

( )e!i/ie(/i

4i"< D? 4i"< K?

4i"< >15?

!ola"?)e!i/ie(/i

M2? Ca )a( 6eri("erak/i

)e(2a(

ka!ei(


7/14

PRESKRIPSI DIET

A< T,a(

- Meme(*i ke6"*a( e(er2i )a( a" 2ii pa/ie( /e8ara peroral /e/ai )e(2a( ke6"*a( pa/ie( a2ar "i)ak "er,a)i komplika/i le6i* la(,"

- Me(2o("rol pro!il lipi) pa/ie(

-Me(2o("rol "eka(a( )ara* pa/ie(

>< Pri(/ip

- Re()a* lemak

- Re()a* lemak ,e(*

- Re()a* kole/"erol

- Re()a* lemak "ra(/

- Re()a* 2aram

- Re()a* pri(

- Ti(22i /era"

C< Sara"

- E(er2i )i6erika( /e/ai )e(2a( ke6"*a( pa/ie( )e(2a( memper*i"(2ka( 6era" 6a)a( a),/"e)? "i(22i 6a)a(? mr? )a( !ak"or ak"i4i"a/

pa/ie( ai" /e6e/ar 5$5& kkal

- Pro"ei( )i6erika( 8kp 1$ G )ari "o"al e(er2i ai" /e6e/ar .#?& 2r@*r; ("k me(22a("i /el a"a ,ari(2a( a(2 r/ak )a( )e2e(era/i

- Lemak )i6erika( re()a* 5$G )ari "o"al e(er2i ai" /e6e/ar &%?1. 2r@*r; )e(2a( ri(8ia(

Lemak ,e(* B 1%G )ari "o"al lemak B &?1. 2r@*r;

Kole/"erol B 5%% m2@*ari

Tra(/ !a" B 'G ke6"*a( e(er2i B 3?#5 2r;

-

Kar6o*i)ra" )i6erika( /e6e/ar '&.?%$ 2r@*r %G )ari "o"al e(er2i;- Sera" mi(imal '% 2r ("k me(8e2a* ko(/"ipa/i

- Na"rim )i6erika( %%-3%% m2@*r ("k me(,a2a "eka(a( )ara* pa/ie(

- Vi"ami( A )i6erika( %% m82 /e6a2ai a("iok/i)a( ("k me(2a"a/i "i(22i(a ra)ikal 6e6a/ )alam "6*

- Vi"ami( C )i6erika( .% m2 /e6a2ai a("iok/i)a( ("k me(2a"a/i "i(22i(a ra)ikal 6e6a/ )alam "6*

- Vi"ami( E )i6erika( 1$ m2 /e6a2ai a("iok/i)a( ("k me(2a"a/i "i(22i(a ra)ikal 6e6a/ )alam "6*


8/14

- >e("k maka(a( 6ia/a? )e(2a( kompo/i/i ' maka( "ama )a( ' /(a8k

- Por/i ke8il a2ar "i)ak memperpara* /e/ak (a!a/ )a( (eri )a)a

D< Ke6"*a( e(er2i )a( a" 2ii

>>I T>-1%%; .%G

&% .%G ' k2

>> a),/"e) A> I>; %?5$ I>

33?$ '; %?5$ '

.?' k2

TEE 1%3 1%?1 /ia; PA 1'?& >> a),/"e); #1 T>;

1%3 1%?1 #1; 1?15 1'?& .?'; #1 1?&; 5$5& kkal

KH %G; '&.?%$ 2r

P 1$G; .#?& 2r

L 5$G; &%?1. 2r

Lemak ,e(* B &?1. 2r

Kole/"erol B 5%% m2

Lemak "ra(/ B 3?#5 2r

Sera" '% 2r

Na %%-3%% m2

Vi" A %% m82


9/14

Vi" C .% m2

Vi" E 1$ m2

Form Men

E(er2i : 5$5& k8al Lemak : &%?1.2r KH : '&.?%$ 2r Sera" : '% 2r

Pro"ei( : .#?& 2r Na : %%-3%% m2


10/14

W!"# Men B!$!n M!"!n!n Ber!# %&'Ener&(

%")!*'

+ro#e(n

%&'

Lem!"

%&'

K,

%&'

Ser!#

%m&'

N!

%m&'

V(#-A

%m)&'

V(#- .

%m&'

V(#- E

%m&'


11/14

S!r!/!n N!( /#($ Na/i 1%% 1&$ # % #% %?' % % % %

%0-0003-00' .!/ )!4 or"el '% &?& %?' %?1 1?# 1?1 13 #&5?5 5?1 %?1

Kem6a(2 kol 5$ ?' %?' %?1 1?# %? #?$ '?' 3 %

Sa+i p"i* '% #?$ %?& %?1 %? %? #?3 .%?. &?$ %?

>a6 8or( 5$ 1#?3 %?# %?5 '?$ %?# 5?' 1?3 %?3 %

P"i* "elr '% 1$ '?5 % %?' % #.


12/14

S7#o#!* 89:3 22 3 10:6 :; 1;3:2 6;1:1 191:3 2:3

S(!n& N!( /#($ Na/i 1%% 1&$ # % #% %?' % % % %

%12-001;-00'S/ ("!n

m!

Ve&e#!7*e

#e!m e&&Telr aam % .'?1 &? ?# %?& % ?#

11# % 1?5

or"el 5$ ?$ %?5 %?1 1?5 %?. 1$ '.'?$ 1?3 %?1

Ta* 5% 1$?5 1? 1 %?# %?5 1?# % % %

=a2(2 5% 51? %?& %?' $ %? '?# 5? 1?5 %

Da( 6a+a(2 1% 5?1 %?1 %?1 %?$ %?5 %? .? %?& %?1

S !/( S/ /api 5%% 1'1?. ?# &?3 .? % 11% 11% 5 %

Sn!)" (!n& B!$ /o#on& Apel #% 5'? %?1 %?5 ?1 1?1 % 5 5?# %?#

%19-00' Ma(22a $% '5?$ %?' %?5 3?$ %?. 1 $ 51?$ %?$

=am6 $% 5$?$ %?# %?' $?. 5?& 1?$ '.?$ .5 %?$

A(22r '% 51?' %?5 %?1 #?& %?5 %? 1?5 1?5 %?5

Ke )7(# Tep(2 "eri2 #% 1#$? #?1 %?# '%?$ 1?1 %?3 % % %

0la pa/ir 1' $%?' % % 1' % %?1 % % %

Telr aam '% #?$ '?3 '?5 %?' % '&?5 $& % %?


13/14

Cokla" 5% .$?# %?3 $?. 15?& % 5?5 %?# % %?5

S7#o#!* =3:; ;:2 ;;:1 192:3 3:3 266:= ;:; 129:1 9:6

M!*!m N!( /#($ Na/i 1%% 1&$ # % #% %?' % % % %

%1-;013-;0' Tm(#em/e !4r

Tempe $% ..?$ .?$ '?3 3?$ %?& ' %?$ % %?$

Ke8am6a* 5% 15?5 1?' %?& 1 %?1 1?# %?5 1? %

or"el 5$ ?$ %?5 %?1 1?5 %?. 1$ '.'?$ 1?3 %?1

>(8i/ 5$ 3?& %?$ %?1 5 %?3 %?3 1?3 5?$ %

Mi(ak $ #'?1 % $ % % % 5$% % %?5

A4!m

/!n&&!n&

mer!$

Aam $% 1#5?# 1'?# .?# % % '?$

1.?$ % %

0la mera* $ 13?$ % % #?& % 1?. % % %

Mi(ak $ #'?1 % $ % % % 5$% % %


14/14

KEBUTU,AN 5$5& .#?& &%?1. '&.?%$ '%%%-

3%%

%% .% 1$

+ERSENTASE .$?& G .& G .3?5 G .3?' G &?' G &.?5 G '3' G '%5 G $&?' G

ncp cardiovascular disease

Documents